News

Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...
Crain's Chicago Business11d
Tempus exec-founded Pathos AI launched a $400M funding round. It's already filling up.
Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development
Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member. Huerga ...
Crain's Chicago Business10y
Biotech and Pharmaceuticals
The fundraise for Pathos AI, established by Ryan Fukushima and Eric Lefkofsky, pushes its valuation to $600 million. On the first day of Gov. JB Pritzker's trade mission to Japan, Sysmex America ...